Founderland Logofounderland
the ★ top ★ 100 ★ marketers ★
SavedSearch
FoundersFounders
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
Product Launches
Industries
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
Investment News
Industries
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
Research & Innovation
Industries
Fintech iconFintechClimate / Social Tech iconClimate / Social TechSaaS iconSaaSHealthtech & Biotech iconHealthtech & BiotecheCommerce iconeCommerceMedia & Entertainment iconMedia & Entertainment
FoundersFounders
Return

Company Page

Syntax Bio

Founders

Nikolas BalanisBrad Merrill

Syntax Bio is a Chicago-based synthetic biology company programming the next generation of cell therapies. Its proprietary Cellgorithm platform uses a CRISPR-based system to automate and accelerate stem cell differentiation, compressing months of costly cell manipulation into days while increasing scale and reproducibility. The company collaborates with biopharma partners and research institutions including Mayo Clinic and Breakthrough T1D to advance regenerative medicines across multiple indications.

Company Founded in 2021

Healthtech & Biotech iconHealthtech & Biotech

Articles about Syntax Bio

Syntax Bio Expands Series A to $14.4M for CRISPR Cell Therapy Platform

Syntax Bio Expands Series A to $14.4M for CRISPR Cell Therapy Platform

Healthtech & Biotech iconHealthtech & BiotechJul 24, 2026
Syntax Bio Expands Series A to $14.4M for CRISPR Stem Cell Platform

Syntax Bio Expands Series A to $14.4M for CRISPR Stem Cell Platform

Healthtech & Biotech iconHealthtech & BiotechJun 27, 2026

About

Dreamwell AIContact UsOur Story

Articles

Product LaunchesInvestment NewsResearch & Innovation

founderland

We Use Cookies

We baked up some cookies – the digital kind. They help Draper run like a well-oiled mid-century machine. Some are essential to the experience, others help us tailor things to your taste. We promise, no crumbs on your blazer. Take a moment to choose what works for you.